Arjun Dhar

Arjun Dhar

Auto-generated profile, based on publicly available information

Arjun Dhar

University of Chicago 1 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease. HOXAhigh T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effective in T-ALL, but biomarkers of response remain undefined. This study aims to evaluate the efficacy of menin inhibition in T-ALL and identify molecular predictors of sensitivity. We tested menin inhibitors (ziftomenib, revumenib, and VTP50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXAhigh and HOXAlow genotypes. In vitro sensitivity assays, xenograft mouse models, transcriptomics, proteomics, and phosphoproteomics were used to characterize drug response. MEF2C modulation experiments and combination studies with cyclin-dependent kinase (CDK) 1/2 and ERK1/2 inhibitors were performed in vitro and in vivo. Menin inhibitors suppressed leukemic growth in a subset of HOXAhigh and HOXAlow primary human T-ALL samples. Similarly, ziftomenib was effective in reducing tumor burden in xenografts without major toxicity. Upon treatment, we observed downregulation of canonical menin targets (HOXA, MEIS1, and MEF2C) and upregulation of T-cell differentiation programs. Phosphoproteomic studies identified MEF2C S222 phosphorylation—mediated by CDK1/2 and ERK1/2—as a predictor of ziftomenib sensitivity in T-ALL. MEF2C overexpression promoted proliferation and ziftomenib resistance, whereas its knockdown impaired growth. Ziftomenib synergized with CDK1/2 and ERK1/2 inhibitors in vitro and improved survival in xenografted mice. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in R/R T-ALL.

4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease. HOXAhigh T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effective in T-ALL, but biomarkers of response remain undefined. This study aims to evaluate the efficacy of menin inhibition in T-ALL and identify molecular predictors of sensitivity. We tested menin inhibitors (ziftomenib, revumenib, and VTP50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXAhigh and HOXAlow genotypes. In vitro sensitivity assays, xenograft mouse models, transcriptomics, proteomics, and phosphoproteomics were used to characterize drug response. MEF2C modulation experiments and combination studies with cyclin-dependent kinase (CDK) 1/2 and ERK1/2 inhibitors were performed in vitro and in vivo. Menin inhibitors suppressed leukemic growth in a subset of HOXAhigh and HOXAlow primary human T-ALL samples. Similarly, ziftomenib was effective in reducing tumor burden in xenografts without major toxicity. Upon treatment, we observed downregulation of canonical menin targets (HOXA, MEIS1, and MEF2C) and upregulation of T-cell differentiation programs. Phosphoproteomic studies identified MEF2C S222 phosphorylation—mediated by CDK1/2 and ERK1/2—as a predictor of ziftomenib sensitivity in T-ALL. MEF2C overexpression promoted proliferation and ziftomenib resistance, whereas its knockdown impaired growth. Ziftomenib synergized with CDK1/2 and ERK1/2 inhibitors in vitro and improved survival in xenografted mice. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in R/R T-ALL.

4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
(A) Dose-response curves represent ziftomenib sensitivities of HOXA-low vs HOXA-high T-ALL cell lines. (B) Heatmap showing RNA expression of HOXB, HOXC, HOXD genes in T-ALL patient samples. (C) Splenectomy specimens of NSG mice engrafted with KARPAS-45 cells and treated with vehicle vs ziftomenib at two different dose levels for 4 weeks. (D,E) Tumor burden in bone marrow and spleen of treated mice. (F) Histopathologic analysis of organs harvested from NSG mice treated with vehicle or ziftomenib at two different dose levels showed increased leukemic cell burden (arrows) in livers of vehicle-treated mice but no microscopic evidence of toxicity to liver, heart, kidney or guts.

4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
(A) Immunoblots confirming MEF2C overexpression in MOLT4 cells. (B) Eight-day growth curves for control vs MEF2C OE MOLT4 cells. (C) Co-treatment with ziftomenib (0.3 µM) and CDK1/2 inhibitor (0.3 µM) in control vs MEF2C OE MOLT4 cells.

4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
Chemical structures of compounds used in this work.

4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
(A) Tables showing death percentage of T-ALL primary cells treated with combinations of ziftomenib and temuterkib (ERK inhibitor) or JNJ-7706621 (CDK1/2 inhibitor). (B) Synergy plot of T-ALL primary cells treated with ziftomenib and temuterkib.